A First-in-Human, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of KPG-818
Latest Information Update: 12 Nov 2019
At a glance
- Drugs KPG 818 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Kangpu Biopharmaceuticals
Most Recent Events
- 10 Oct 2019 Results published in the Kangpu Biopharmaceuticals Media Release
- 10 Oct 2019 Status changed from recruiting to completed, according to a Kangpu Biopharmaceuticals media release.
- 12 Aug 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.